Neurosense Therapeutics is trading 17.02% down at $1.95, with no new company announcement identified to explain the October 28 pre-market decline. - An October 26 PrimeC access collaboration targeted initial revenue in the first half of 2027, but does not establish a cause for the drop. - Commentary updated October 28 questioned the commercialization pathway and noted the stock had closed below a Nasdaq delisting-related threshold; available reporting does not confirm this caused the move. - Supplied broader-market indicators were mixed, not a clear same-direction explanation.